Since we found that SEs are associated to NSMCE2 and MAL2 expression in breast tumors, we hypothesized that in breast cancer cells, expression of these genes should be reduced when disrupting the SE-enhancing function by blocking the binding of BRD4 to SEs with the inhibitors JQ1 or IBET151 [44, 45]. This evidence concerns the gene BRD4 and breast neoplasm.